• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.在非酒精性脂肪性肝炎的多个实验模型中,肾脏外源性物质转运体的表达发生了改变。
Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.
2
Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.利用实验性啮齿动物模型模拟人类非酒精性脂肪性肝炎相关的药物转运体表达变化。
Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.
3
Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎中二甲双胍分布改变的机制。
Diabetes. 2015 Sep;64(9):3305-13. doi: 10.2337/db14-1947. Epub 2015 May 27.
4
Representative Rodent Models for Renal Transporter Alterations in Human Nonalcoholic Steatohepatitis.用于研究人类非酒精性脂肪性肝炎中肾脏转运蛋白改变的代表性啮齿类动物模型。
Drug Metab Dispos. 2023 Aug;51(8):970-981. doi: 10.1124/dmd.122.001133. Epub 2023 May 3.
5
Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.非酒精性脂肪性肝炎中转运蛋白活性的变化:采用血浆粪卟啉原Ⅰ和Ⅲ评估。
J Pharmacol Exp Ther. 2021 Jan;376(1):29-39. doi: 10.1124/jpet.120.000291. Epub 2020 Oct 30.
6
Gene-by-Environment Interaction of Bcrp and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.Bcrp 基因-环境相互作用和蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝炎改变 SN-38 的处置。
Drug Metab Dispos. 2018 Nov;46(11):1478-1486. doi: 10.1124/dmd.118.082081. Epub 2018 Aug 30.
7
Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats.艾塞那匹克高胆红素血症大鼠肝脏和肾脏中多药耐药相关蛋白3表达增加。
J Gastroenterol Hepatol. 2004 Feb;19(2):146-53. doi: 10.1111/j.1440-1746.2004.03275.x.
8
Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.在非酒精性脂肪性肝病的啮齿动物模型中,外排转运蛋白的表达和对乙酰氨基酚代谢产物的排泄发生了改变。
Drug Metab Dispos. 2007 Oct;35(10):1970-8. doi: 10.1124/dmd.107.015107. Epub 2007 Jul 19.
9
Synergistic interaction between genetics and disease on pravastatin disposition.遗传学与疾病在普伐他汀处置方面的协同相互作用。
J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.
10
Effect of caloric restriction and AMPK activation on hepatic nuclear receptor, biotransformation enzyme, and transporter expression in lean and obese mice.热量限制和 AMPK 激活对 lean 和 obese 小鼠肝核受体、生物转化酶和转运体表达的影响。
Pharm Res. 2013 Sep;30(9):2232-47. doi: 10.1007/s11095-013-1140-2. Epub 2013 Aug 16.

引用本文的文献

1
Western diet exacerbates a murine model of Balkan nephropathy.西方饮食会加重巴尔干肾病的小鼠模型。
Am J Physiol Renal Physiol. 2025 Jan 1;328(1):F15-F28. doi: 10.1152/ajprenal.00185.2024. Epub 2024 Nov 7.
2
Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.非酒精性脂肪性肝炎期间顺铂药代动力学的改变导致肾毒性降低。
Acta Pharm Sin B. 2021 Dec;11(12):3869-3878. doi: 10.1016/j.apsb.2021.05.030. Epub 2021 Jun 2.
3
Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.非酒精性脂肪性肝炎小鼠模型中减弱的赭曲霉毒素 A 转运蛋白表达可预防近曲小管毒性。
Drug Metab Dispos. 2022 Oct;50(10):1389-1395. doi: 10.1124/dmd.121.000451. Epub 2021 Dec 17.
4
Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.肾脏中的药物转运体:物种差异、疾病状态及分子对接的研究视角
Front Pharmacol. 2021 Nov 29;12:746208. doi: 10.3389/fphar.2021.746208. eCollection 2021.
5
Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎中吗啡和吗啡-3-葡萄糖醛酸的基于生理学的药代动力学模型。
Clin Pharmacol Ther. 2021 Mar;109(3):676-687. doi: 10.1002/cpt.2037. Epub 2020 Nov 6.
6
Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract.肝功能衰竭的肝外药物转运体:重点关注肾脏和胃肠道。
Int J Mol Sci. 2020 Aug 10;21(16):5737. doi: 10.3390/ijms21165737.
7
Modulation of Tetrachloroethylene-Associated Kidney Effects by Nonalcoholic Fatty Liver or Steatohepatitis in Male C57BL/6J Mice.四氯乙烯相关性肾损伤在雄性 C57BL/6J 小鼠中非酒精性脂肪肝或脂肪性肝炎模型中的作用调节。
Toxicol Sci. 2019 Jan 1;167(1):126-137. doi: 10.1093/toxsci/kfy223.
8
Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.超重和肥胖青少年中二甲双胍清除率增加:一项随机对照试验的药代动力学亚研究。
Paediatr Drugs. 2018 Aug;20(4):365-374. doi: 10.1007/s40272-018-0293-1.
9
Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.非酒精性脂肪性肝炎(NASH)患者和健康成年人中吗啡的群体药代动力学
CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):331-339. doi: 10.1002/psp4.12185. Epub 2017 Apr 18.
10
Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.非酒精性脂肪性肝炎对阿德福韦肾滤过及分泌的影响。
Biochem Pharmacol. 2016 Sep 1;115:144-51. doi: 10.1016/j.bcp.2016.07.001. Epub 2016 Jul 2.

本文引用的文献

1
Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.胆汁酸可逆转法尼醇 X 受体缺陷小鼠非酒精性脂肪性肝炎模型中的脂肪变性。
Biochem Biophys Res Commun. 2014 May 23;448(1):50-5. doi: 10.1016/j.bbrc.2014.04.048. Epub 2014 Apr 18.
2
Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.利用实验性啮齿动物模型模拟人类非酒精性脂肪性肝炎相关的药物转运体表达变化。
Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.
3
Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.非酒精性脂肪性肝炎和前瘤病变发生在肥胖和高血压大鼠的肝脏中:EGCG 对肝脏病变发展的抑制作用。
Cancer Lett. 2014 Jan 1;342(1):60-9. doi: 10.1016/j.canlet.2013.08.031. Epub 2013 Aug 24.
4
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.肝脏基因表达谱可区分无症状轻度与重度非酒精性脂肪性肝病患者。
Hepatology. 2014 Feb;59(2):471-82. doi: 10.1002/hep.26661. Epub 2013 Dec 13.
5
JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats.JBP485 通过调节大鼠 Oat1 和 Oat3 的表达和功能改善庆大霉素诱导的急性肾衰竭。
Toxicol Appl Pharmacol. 2013 Sep 1;271(2):285-95. doi: 10.1016/j.taap.2013.04.029. Epub 2013 May 23.
6
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.非酒精性脂肪性肝病:当前的问题和新的治疗方法。
Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0.
7
Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment.非酒精性脂肪性肝病与代谢综合征:临床意义与治疗。
Nutr Clin Pract. 2013 Feb;28(1):40-51. doi: 10.1177/0884533612470464. Epub 2013 Jan 3.
8
Renal transporters in drug development.药物研发中的肾脏转运体。
Annu Rev Pharmacol Toxicol. 2013;53:503-29. doi: 10.1146/annurev-pharmtox-011112-140317. Epub 2012 Nov 8.
9
TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis.非酒精性脂肪性肝炎患者的 TNF-α 信使核糖核酸(mRNA)。
Eur Cytokine Netw. 2012 Jul-Sep;23(3):107-11. doi: 10.1684/ecn.2012.0313.
10
Altered arsenic disposition in experimental nonalcoholic fatty liver disease.实验性非酒精性脂肪性肝病中砷处置的改变。
Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

在非酒精性脂肪性肝炎的多个实验模型中,肾脏外源性物质转运体的表达发生了改变。

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

作者信息

Canet Mark J, Hardwick Rhiannon N, Lake April D, Dzierlenga Anika L, Clarke John D, Goedken Michael J, Cherrington Nathan J

机构信息

University of Arizona, Department of Pharmacology and Toxicology, Tucson, Arizona (M.J.C., R.N.H., A.D.L., A.L.D., J.D.C., N.J.C.); and Rutgers University, Office of Translational Science, New Brunswick, New Jersey (M.J.G.).

University of Arizona, Department of Pharmacology and Toxicology, Tucson, Arizona (M.J.C., R.N.H., A.D.L., A.L.D., J.D.C., N.J.C.); and Rutgers University, Office of Translational Science, New Brunswick, New Jersey (M.J.G.)

出版信息

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

DOI:10.1124/dmd.114.060574
PMID:25488932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4293398/
Abstract

Nonalcoholic fatty liver disease is the most common chronic liver disease, which can progress to nonalcoholic steatohepatitis (NASH). Previous investigations demonstrated alterations in the expression and activity of hepatic drug transporters in NASH. Moreover, studies using rodent models of cholestasis suggest that compensatory changes in kidney transporter expression occur to facilitate renal excretion during states of hepatic stress; however, little information is currently known regarding extrahepatic regulation of drug transporters in NASH. The purpose of the current study was to investigate the possibility of renal drug transporter regulation in NASH across multiple experimental rodent models. Both rat and mouse NASH models were used in this investigation and include: the methionine and choline-deficient (MCD) diet, atherogenic diet, fa/fa rat, ob/ob and db/db mice. Histologic and pathologic evaluations confirmed that the MCD and atherogenic rats as well as the ob/ob and db/db mice all developed NASH. In contrast, the fa/fa rats did not develop NASH but did develop extensive renal injury compared with the other models. Renal mRNA and protein analyses of xenobiotic transporters suggest that compensatory changes occur in NASH to favor increased xenobiotic secretion. Specifically, both apical efflux and basolateral uptake transporters are induced, whereas apical uptake transporter expression is repressed. These results suggest that NASH may alter the expression and potentially function of renal drug transporters, thereby impacting drug elimination mechanisms in the kidney.

摘要

非酒精性脂肪性肝病是最常见的慢性肝病,可进展为非酒精性脂肪性肝炎(NASH)。先前的研究表明,NASH中肝脏药物转运体的表达和活性发生了改变。此外,使用胆汁淤积啮齿动物模型的研究表明,在肝脏应激状态下,肾脏转运体表达会发生代偿性变化,以促进肾脏排泄;然而,目前关于NASH中外周药物转运体调节的信息知之甚少。本研究的目的是通过多个实验性啮齿动物模型研究NASH中肾脏药物转运体调节的可能性。本研究使用了大鼠和小鼠NASH模型,包括:蛋氨酸和胆碱缺乏(MCD)饮食、致动脉粥样硬化饮食、fa/fa大鼠、ob/ob和db/db小鼠。组织学和病理学评估证实,MCD和致动脉粥样硬化大鼠以及ob/ob和db/db小鼠均发展为NASH。相比之下,fa/fa大鼠未发展为NASH,但与其他模型相比,确实出现了广泛的肾损伤。对外源性物质转运体的肾脏mRNA和蛋白质分析表明,NASH中发生了代偿性变化,有利于增加外源性物质的分泌。具体而言,顶端外排和基底外侧摄取转运体均被诱导,而顶端摄取转运体的表达受到抑制。这些结果表明,NASH可能会改变肾脏药物转运体的表达及其潜在功能,从而影响肾脏中的药物消除机制。